Clinical Topics & News
SAN DIEGO – The benefit of the switch was observed regardless of previous treatment status.
SAN DIEGO – Dangerous viral brain disease is more likely to strike at-risk MS patients who rely on standard-interval dosing.
SAN DIEGO – Small study of oral drugs finds they’re similar in terms of efficacy and adverse effects, and both can be used “with equal confidence...
SAN DIEGO – The comparative effectiveness of delayed-release dimethyl fumarate was analyzed against fingolimod and glatiramer acetate.
The 2016 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) criteria have accuracy similar to that of the 2010 McDonald criteria in...
Rituximab is associated with a lower drug discontinuation rate than all other commonly prescribed disease-modifying treatments (DMTs) used as...
Stuart D. Cook, MD, and Abdul Rahman Alchaki, MDDr. Cook is the Ruth Dunietz Kushner and Michael Jay Serwitz Professor of Neurology/Neurosciences...
Generic glatiramer acetate remains effective and safe over two years of treatment for patients with relapsing-remitting multiple sclerosis (MS),...
Changes to the 2010 McDonald multiple sclerosis diagnostic criteria aim to promote earlier diagnosis and discourage misdiagnosis.
Retrospective study of 2010 McDonald and 2016 MAGNIMS criteria indicates a need for increased specificity for MS diagnosis.